Comparative Pharmacology
Head-to-head clinical analysis: MIDAMOR versus TRIAMTERENE AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIDAMOR versus TRIAMTERENE AND HYDROCHLOROTHIAZIDE.
MIDAMOR vs TRIAMTERENE AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amiloride is a potassium-sparing diuretic that blocks epithelial sodium channels (ENaC) in the distal convoluted tubule and collecting duct, reducing sodium reabsorption and potassium excretion.
Triamterene inhibits sodium reabsorption in the distal renal tubules by blocking epithelial sodium channels, reducing potassium excretion. Hydrochlorothiazide inhibits sodium and chloride reabsorption in the distal convoluted tubule by binding to the thiazide-sensitive sodium-chloride cotransporter, leading to increased diuresis and natriuresis.
5 mg orally once daily, increased to 10 mg if needed; maximum 20 mg/day.
Adults: 1 capsule (triamterene 37.5 mg / hydrochlorothiazide 25 mg) orally once daily or twice daily; maximum triamterene 150 mg/day.
None Documented
None Documented
Terminal half-life 6-9 hours; prolonged in renal impairment (up to 20 hours) and in heart failure
Triamterene: 1.5-2.5 hours (terminal), prolonged in hepatic impairment; Hydrochlorothiazide: 6-15 hours (terminal), prolonged in renal impairment.
Renal: 80-90% as unchanged drug; biliary/fecal: <5%
Triamterene: renal 21-50% (unchanged) and 40-54% (metabolites); Hydrochlorothiazide: renal >95% unchanged.
Category C
Category A/B
Potassium-Sparing Diuretic
Potassium-Sparing Diuretic